Rezatapopt Takes Aim at Previously Untargetable p53 ...
Rezatapopt, a first-in-class p53 Y220C reactivator, shows promise in targeting the previously 'undruggable' p53 Y220C mutation in advanced solid tumors. Currently in phase 1/2 PYNNACLE study, it has demonstrated efficacy and tolerability across various tumor types, with a recommended phase 2 dose of 2000 mg daily. Early results indicate notable activity in refractory cancers, with ongoing phase 2 studies aiming to further clarify its effectiveness and potential for FDA approval.
Related Clinical Trials
Reference News
Rezatapopt, a first-in-class p53 Y220C reactivator, shows promise in targeting the previously 'undruggable' p53 Y220C mutation in advanced solid tumors. Currently in phase 1/2 PYNNACLE study, it has demonstrated efficacy and tolerability across various tumor types, with a recommended phase 2 dose of 2000 mg daily. Early results indicate notable activity in refractory cancers, with ongoing phase 2 studies aiming to further clarify its effectiveness and potential for FDA approval.